Associations between attention-deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study

Tor-Arne Hegvik1,2 · Johanne Telnes Instanes1,2,3 · Jan Haavik1,2,4 · Kari Klungsøyr3,5 · Anders Engeland3,6

Received: 7 June 2017 / Accepted: 21 September 2017 / Published online: 5 October 2017 © The Author(s) 2017. This article is an open access publication

Abstract
Several studies have demonstrated associations between neuropsychiatric disorders, such as attention-deficit/hyperactivity disorder (ADHD), and the immune system, including autoimmune diseases. Since ADHD and many autoimmune diseases show sex-specific properties, such associations may also differ by sex. Using Norwegian national registries, we performed a cross-sectional study based on a cohort of 2,500,118 individuals to investigate whether ADHD is associated with common autoimmune diseases. Associations between ADHD and autoimmune diseases in females and males were investigated with logistic regression and effect modification by sex was evaluated. Several subanalyses were performed. The strongest association was found between ADHD and psoriasis in females, adjusted odds ratio (adjOR) = 1.57 (95% confidence interval: 1.46–1.68) and males, adjOR = 1.31 (1.23–1.40); p value for interaction < 0.0001. Furthermore, among females, ADHD was associated with Crohn’s disease, adjOR = 1.44 (1.16–1.79) and ulcerative colitis, adjOR = 1.28 (1.06–1.54). In contrast, males with ADHD had lower odds of Crohn’s disease, adjOR = 0.71 (0.54–0.92), in addition to a trend for lower odds of ulcerative colitis, adjOR = 0.86 (0.71–1.03); p values for interaction < 0.0001 and 0.0023, respectively. In a group of females where information on smoking and body mass index was available, adjustment for these potential mediators did not substantially alter the associations. Our findings support previously reported associations between ADHD and diseases of the immune system. The associations differ by sex, suggesting that sex-specific immune-mediated neurodevelopmental processes may be involved in the etiology of ADHD.

Keywords ADHD · Autoimmunity · Neuropsychiatry · Comorbidity · Psoriasis · Neuroimmunology

Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the symptoms of inattentiveness, hyperactivity, and impulsivity. The symptoms of this childhood-onset condition often persist into adulthood [1]. Furthermore, patients often suffer from comorbid...
psychiatric disorders [2, 3] and face socioeconomic hardship [4]. The etiology of ADHD is largely unknown, but in twin studies, the heritability of the disorder has been estimated to be 70–80%, implicating a strong genetic basis [1, 5, 6]. Environmental factors and perinatal factors such as preterm birth and growth restriction have also been shown to influence the development of ADHD [1, 7, 8].

Numerous studies have reported associations between neuropsychiatric disorders and immune system abnormalities [9–16]. However, these associations remain uncertain [17–19]. Likewise, several immune-related disorders, such as atopic dermatitis, asthma, ankylosing spondylitis, ulcerative colitis (UC), juvenile arthritis, autoimmune thyroid disease and celiac disease have been associated with ADHD [20–23]. Additionally, maternal autoimmunity has been associated with offspring ADHD, implying that maternal immune system dysfunction may affect the in utero environment and again fetal neurodevelopment [21, 24]. Despite the genetic architecture of ADHD being relatively unknown, some tentative genetic associations between ADHD and the immune system have been noted. For example, a study on genetic pathways of ADHD, which was based on genome-wide association studies (GWAS), found an increased burden of polymorphisms in and around genes involved in toll-like receptor signaling [25]. These signaling pathways are highly involved in the innate immune responses and have also been shown to regulate hippocampal plasticity and neurogenesis, and memory formation [26]. Furthermore, the single nucleotide polymorphism (SNP) which showed the strongest association signal in a recent ADHD GWAS, which included more than 20,000 ADHD patients and 35,000 controls, is located in the gene ST3GAL3 [27]. Knockout of the ST3GAL3 gene affects both eosinophilic immune responses [28] and brain development [29].

ADHD has an approximate male:female ratio of 3:1 during childhood and adolescence, which approaches 1:1 in adults [1]. Moreover, ADHD displays sex-specific manifestations [30]. For example, females are more often primarily affected by inattention, whereas males more often display additional symptoms of hyperactivity and impulsivity [31]. Likewise, autoimmune diseases have prevalence rates and symptom burdens that may differ by sex [32–34]. Interestingly, GWASs have reported SNPs to be associated with an autoimmune disease in one sex, but not the other [35] and genetic effects being in opposite directions depending on sex have been reported [36, 37]. Further, sex hormones are believed to have immune-modulating properties, as exemplified by symptom remission of multiple sclerosis and rheumatoid arthritis during pregnancy [33, 34]. Neural functioning might also be regulated by these hormones, as demonstrated by menstrual cycle-associated seizures of certain types of epilepsy [38]. Besides, behavior may be affected by sex hormones. For instance, females exposed to elevated prenatal androgen levels may develop more aggressive behavior later in life as compared to non-exposed females [39], and moreover, aggressive behavior is associated with ADHD [40].

In sum, if sex-specific genetic pleiotropy, or other sex-specific mechanisms, underlie any associations between ADHD and autoimmunity, these associations may differ substantially by sex. In other words, sex could be an effect measure modifier.

To further explore possible associations between autoimmunity and ADHD, and to evaluate whether these associations vary by sex, we conducted a large cross-sectional study based on Norwegian national registries.

Materials and methods

The Medical Birth Registry of Norway (MBRN)

The Medical Birth Registry of Norway (MBRN) was established in 1967 to collect medical and familial information on parents and births in Norway [41]. Registration in the MBRN is mandatory for all pregnancies from 16 completed weeks of gestation, and is based on a standardized notification form. Maternal smoking habits have been included in the registry since December 1998, but is one of few variables where mothers can refuse registration. Still, for approximately 84% of the births smoking information is registered. Since 2006, electronic notification of births to the MBRN has been introduced gradually, based on standardized extraction from medical records at the delivery units, and has included information on maternal height and weight before and at the end of pregnancy. However, it was not until 2014 that electronic notification was in place at all delivery units and in 2013, information on height and weight was still missing for approximately 36% of the pregnancies.

Data for the current study was obtained for all live births in the MBRN from January 1st 1967 to December 31st 2013.

The Norwegian Prescription Database (NorPD)

The Norwegian Prescription Database (NorPD) was established in 2004 and provides information on all medical prescriptions dispensed to patients from all Norwegian pharmacies, and includes the Anatomical Therapeutic Chemical Classification System (ATC) codes [42]. Information on medication received during hospitalization is not available on an individual basis. From 2008, the NorPD has included information on diagnostic codes for reimbursed medication based on either the International Classification of Primary Care (ICPC) or the International Statistical Classification of Diseases and Related Health Problems 10th version (ICD-10), used in specialist health care. From 2004 to 2008, the NorPD also included diagnostic codes for prescribed

Springer
reimbursed medication. However, these diagnostic codes were less specific, and therefore not used in this study. For the present study, information was obtained for all dispensed drugs between January 1st 2004 and December 31st 2015.

**The National Education Database**

The National Education Database holds information on the education of all Norwegian citizens from the age of 16 years. The database covers all levels of education from primary school to PhD-level. For the present study, data on education as registered in 2012 was available.

**The National Registry**

The National Registry supplied information on emigration and dates of death.

**Included individuals and record linkage**

All individuals registered in the MBRN as born between 1967 and 2011, who were alive and residing in Norway on December 31st 2015, were included in the study. In addition, the mothers of those registered in the MBRN between 1998 and 2013, were identified for supplementary analyses allowing adjustment for body mass index (BMI) and smoking. Mothers who had died or emigrated by December 31st 2015 were excluded from these supplementary analyses (see below).

All Norwegian citizens have a unique personal identification number. This number was used to establish linkage between the registries.

**ADHD case definition**

ADHD cases were defined as all individuals, regardless of age, who had been dispensed reimbursed ADHD medication (ATC N06BA) \( (n = 63,721) \), without reimbursement codes for “narcolepsy”, G47 in ICD-10 and “sleep disturbance”, P06 in ICPC \( (n = 407) \), during 2004–2015. The remaining population served as the comparison group \( (n = 2,436,397) \).

**Autoimmune diseases**

Autoimmune disease cases were defined from reimbursement codes or specific dispensed drugs corresponding to one of several predefined and common autoimmune diseases. The set of diseases was based on a Danish study describing the prevalence of 30 autoimmune diseases [43]. The estimated coverage of the autoimmune disease cases was compared with the reported prevalence rates of the autoimmune diseases in the general population by utilizing Eaton et al. 2010 [43] in addition to Norwegian and Swedish prevalence studies. Autoimmune diseases where the available reimbursement codes were considered too unspecific, that had unlikely prevalence estimates, or with less than 1000 cases in total \((< 4 \text{ pr } 10,000)\), were excluded. Nine autoimmune diseases passed the inclusion criteria (see Table 1) and were included in the study.

| Disease/disorder       | Definition of case                                                                 |
|------------------------|-----------------------------------------------------------------------------------|
| ADHD                   | Prescribed and dispensed at least one reimbursed drug once with ATC-code N06BA excluding those with reimbursement code ICD-10 G47 (narcolepsy) or ICPC P06 (sleep disturbance) |
| Ankylosing spondylitis | Prescribed and dispensed at least one drug once with reimbursement code ICD-10 M45 |
| Crohn’s disease        | Prescribed and dispensed at least one drug once with reimbursement code ICD-10 K50 |
| Iridocyclitis          | Prescribed and dispensed at least one drug once with reimbursement code ICD-10 H20 |
| Multiple sclerosis     | Prescribed and dispensed at least one drug once with ATC-code L03AB07, L03AB08, L03AB13, L03AX13, L04AA23, L04AA27, L04AA31, L04AA34, L04AC01, N07XX07 or N07XX09 |
| Psoriasis              | Prescribed and dispensed at least one drug once with reimbursement code ICD-10 L40 or ICPC S91 |
| Rheumatoid arthritis   | Prescribed and dispensed at least one drug once with reimbursement codes ICD-10 M05 or M06 |
| SLE                    | Prescribed and dispensed at least one drug once with reimbursement code ICD-10 M32 |
| Type 1 diabetes        | Prescribed and dispensed at least one drug once with reimbursement code ICD-10 E10 or ICPC T89, excluding those who have been dispensed at least one drug once with ATC-code A10B |
| Ulcerative colitis     | Prescribed and dispensed at least one drug once with reimbursement code ICD-10 K51 |

*ADHD* attention-deficit/hyperactivity disorder, *ATC* Anatomical Therapeutic Chemical Classification System, *ICD-10* International Statistical Classification of Diseases and Related Health Problems 10, *ICPC* International Classification of Primary Care, *SLE* systemic lupus erythematosus

*The ICD-10 and ICPC codes for multiple sclerosis are not used in Norway at drug prescribement due to health-regulatory reasons. ATC codes for multiple sclerosis-specific drugs therefore defined multiple sclerosis.*
Statistical analysis

Possible associations between ADHD and the autoimmune diseases were estimated as odds ratios (OR) with 95% confidence intervals (CI) using logistic regression. *p* values are presented uncorrected for multiple testing. The threshold for statistical significance was adjusted *ad modum* Bonferroni (*p* = 0.05 divided by the number of autoimmune diseases included in the primary analyses) to *p* = 0.0056. The threshold for nominal significance was defined as *p* = 0.05. Data management and statistical analyses were performed with R [44], RStudio [45] and IBM SPSS [46].

Primary analyses

In the primary analyses, associations between autoimmune diseases and ADHD were investigated with adjustment for age as a continuous covariate, except for type 1 diabetes where age was categorized into four (years of age in 2015: 4–10; 11–15; 16–20; 21–48). All analyses were stratified by sex [1, 30–34]. Effect modification by sex was evaluated on a multiplicative scale including an interaction term in the logistic regression model, and statistical significance was evaluated by Wald test.

Socioeconomic status as defined by maternal education was adjusted for as a categorical covariate with three categories, low (< 10 years of education), medium (10–12 years) and high (> 12 years).

Statistically significant associations in the primary analyses were further investigated in supplementary analyses concerning potential confounders, mediators and biases.

Adjustment for smoking and body mass index (mother analyses)

Tobacco smoking and BMI may be mediating factors between ADHD and autoimmune diseases. Smoking is known to be associated with ADHD [47, 48] and has been associated with increased risk of several autoimmune diseases in prospective studies [49–51]. The similar applies to BMI in ADHD [20, 52] and autoimmunity [53–56]. To conduct a sensitivity analysis on whether the associations discovered in the main analyses were mediated mainly through smoking and/or BMI, a new study population including data on smoking and BMI was defined. The MBRN supplied data on smoking for women giving birth from December 1998 to 2013, and these mothers defined the study population when assessing the effect of smoking (from now on referred to as the “mother analyses”). Smoking during pregnancy was used as a proxy for smoking at linkage. As proxy for BMI at linkage, pre-pregnant BMI (kg/m²) of the mothers was used. Mothers with registered height below 130 cm or BMI below 15 or above 60 were set to missing as these values were considered biologically implausible. Socioeconomic status was defined as the education of the mother in 2012 categorized into three: low (< 10 years), medium (10–12 years) and high (> 12 years). For females who had given birth to several children, only data from the last registered birth was included.

Logistic regression was used to investigate associations between ADHD and autoimmune diseases among these mothers with and without adjustment for the mother’s smoking habits and with education as covariate. Further, a similar logistic regression was conducted with the inclusion of BMI, modelled as a continuous covariate, in addition to smoking and education. Substantial attenuation of the estimated associations between ADHD and autoimmune diseases when adjusting for smoking and BMI, would indicate that much of the effect of ADHD on these diseases might be mediated through these mediators [57, 58].

Several additional subanalyses were also conducted, when possible, to scrutinize statistically significant associations identified in the primary analyses (see supplemental material).

Results

Demographics

We identified a total of 2,500,118 individuals in the MBRN fulfilling our inclusion criteria for the primary analyses, 1,219,669 females and 1,280,449 males.

22,878 (1.9%) of the females had ADHD with the highest prevalence among those born in 1993 (3.5%). Of the males, 40,843 (3.2%) had ADHD, with the highest prevalence among those born in 1996 (6.8%) (supplementary Fig. 1). ADHD was associated with lower socioeconomic status, as defined by maternal educational level (see Table 2).

The total number of patients per autoimmune disease ranged from 1197 (5 per 10,000) for systemic lupus erythematosus (SLE) to 62,418 (250 per 10,000) for psoriasis. The female-to-male ratios varied across the autoimmune diseases, with 42.3% of type 1 diabetes patients being female, to 85.5% of SLE patients. All autoimmune diseases increased in prevalence with age (supplementary Fig. 1). All autoimmune diseases were associated with lower socioeconomic status.

Primary analyses

ADHD was significantly associated with increased odds of psoriasis in both females, adjusted (adj) OR = 1.57 (95% CI 1.46–1.68) and males, adjOR = 1.31 (95% CI 1.23–1.40). Associations were significantly stronger for females than males, *p* value for interaction by sex = 4.4 × 10^-6.
Sex differences were even larger for Crohn’s disease (CD) and UC: Females with ADHD had a significantly higher odds of CD, adjOR 1.44 (95% CI 1.16–1.79), and UC, adjOR = 1.28 (95% CI 1.06–1.54), than females without ADHD. Males with ADHD, on the other hand, seemed protected, with a lower odds of CD than males without ADHD, adjOR = 0.71 (95% CI 0.54–0.92; nominal statistically significant), and a tendency to lower odds of UC, adjOR = 0.86 (95% CI 0.71–1.03). There were significant interaction effects between ADHD and sex on the odds for both CD, \( p = 3.6 \times 10^{-5} \), and UC, \( p = 0.0023 \). Despite not reaching the threshold for statistical significance, UC was taken to supplementary analyses as UC shares many characteristics with CD and displayed statistically significant interaction effects by sex.

ADHD was further associated with lower odds of ankylosing spondylitis among females, but only at nominal statistical significance, adjOR = 0.56 (95% CI 0.32–0.92; nominal statistically significant), and a tendency to lower odds of UC, adjOR = 0.86 (95% CI 0.71–1.03). There were significant interaction effects between ADHD and sex on the odds for both CD, \( p = 3.6 \times 10^{-5} \), and UC, \( p = 0.0023 \). Despite not reaching the threshold for statistical significance, UC was taken to supplementary analyses as UC shares many characteristics with CD and displayed statistically significant interaction effects by sex.

ADHD was associated with increased odds of psoriasis, adjOR = 1.62 (95% CI 1.44–1.81) also after additional adjustment for smoking, adjOR = 1.49 (95% CI 1.33–1.67) and BMI, adjOR = 1.29 (95% CI 1.04–1.60).

ADHD was associated with CD, adjOR = 1.77 (95% CI 1.23–2.54) and UC, adjOR = 1.87 (95% CI 1.42–2.46). Adjustment for smoking did not materially change ADHD’s association with CD, adjOR = 1.63 (95% CI 1.13–2.34) nor UC, adjOR = 1.90 (95% CI 1.45–2.50). Similarly, additional adjustment for BMI did not alter the ADHD-CD association, adjOR = 2.20 (95% CI 1.24–3.88) nor the ADHD-UC association, adjOR = 2.10 (95% CI 1.30–3.39).

Similar analyses stratified by smoking and overweight, BMI < 25 or ≥ 25, were also conducted. The results were in line with the presented findings (data and results not presented). See Table 4 for detailed results.

### Table 2 Characteristics of the study population in the primary analyses

| Disease/disorder           | n (per 10 000) | Mean age in 2015 | Females (%) | Maternal education % | Information missing |
|----------------------------|----------------|------------------|-------------|----------------------|---------------------|
|                            |                |                  |             | Low (< 10 years)     | Medium (10–12 years) | High (> 12 years)   |
| Total study sample         | 2,500,118      | 25.8             | 1,219,669 (48.8) | 23.1 | 42.0 | 33.9 | 0.1 |
| ADHD                      | 63,721 (255)   | 23.4             | 22,878 (35.9) | 31.5 | 42.1 | 25.7 | 0.7 |
| Ankylosing spondylitis     | 3504 (14)      | 37.4             | 1480 (42.2)  | 28.9 | 47.6 | 23.0 | 0.5 |
| Crohn's disease            | 6292 (25)      | 32.1             | 3284 (52.2)  | 27.6 | 46.0 | 25.9 | 0.5 |
| Iridocyclitis              | 7596 (30)      | 34.0             | 3470 (45.7)  | 26.3 | 46.7 | 26.6 | 0.4 |
| Multiple sclerosis         | 3739 (15)      | 38.1             | 2621 (70.1)  | 29.6 | 49.6 | 20.5 | 0.4 |
| Psoriasis                  | 62,418 (250)   | 33.8             | 32,190 (51.6) | 29.6 | 46.2 | 23.7 | 0.6 |
| Rheumatoid arthritis       | 8560 (34)      | 37.2             | 5662 (66.1)  | 30.9 | 47.8 | 20.8 | 0.4 |
| SLE                        | 1197 (5)       | 35.9             | 1024 (85.5)  | 30.2 | 45.6 | 23.6 | 0.7 |
| Type 1 diabetes            | 14,273 (57)    | 29.5             | 6041 (42.3)  | 23.7 | 46.4 | 29.6 | 0.4 |
| Ulcerative colitis         | 10,960 (44)    | 34.3             | 5392 (49.2)  | 26.3 | 47.3 | 26.0 | 0.4 |

ADHD attention-deficit/hyperactivity disorder, SLE systemic lupus erythematosus
Fig. 1 Sex-specific associations (odds ratios with 95% confidence intervals adjusted for age and maternal education) between ADHD and the autoimmune diseases investigated in the primary analyses.

Table 3 Associations between ADHD and autoimmune diseases among males and females, and the p-value for the interaction between ADHD and sex, with adjustment for age and maternal education.

| Autoimmune disease | Females | Males | All |
|--------------------|---------|-------|-----|
|                    | Adjusted for age | Adjusted for age and maternal education | Adjusted for age | Adjusted for age and maternal education | p value of interaction between ADHD and sex adjusted for age and maternal education |
| Ankylosing spondylitis | 0.56 (0.32–0.96) | 0.56 (0.32–0.96) | 1.17 (0.88–1.56) | 1.16 (0.87–1.55) | 0.021 |
| Crohn’s disease | **1.47 (1.18–1.82)** | **1.44 (1.16–1.79)** | 0.71 (0.54–0.92) | 0.71 (0.54–0.92) | **3.6 × 10^{-5}** |
| Iridocyclitis | 0.84 (0.64–1.12) | 0.83 (0.63–1.10) | 1.11 (0.92–1.34) | 1.11 (0.92–1.34) | 0.084 |
| Multiple sclerosis | 1.20 (0.90–1.60) | 1.19 (0.90–1.59) | 0.95 (0.61–1.46) | 0.95 (0.61–1.46) | 0.35 |
| Psoriasis | **1.60 (1.49–1.72)** | **1.57 (1.46–1.68)** | **1.34 (1.25–1.43)** | **1.31 (1.23–1.40)** | **4.4 × 10^{-6}** |
| Rheumatoid arthritis | 1.05 (0.85–1.28) | 1.02 (0.83–1.26) | 1.01 (0.78–1.30) | 0.98 (0.75–1.26) | 0.65 |
| SLE | 1.26 (0.82–1.94) | 1.25 (0.81–1.93) | 1.28 (0.52–3.13) | 1.29 (0.53–3.16) | 0.98 |
| Type 1 diabetes^a | 1.00 (0.83–1.19) | 1.00 (0.84–1.20) | 0.98 (0.87–1.11) | 0.98 (0.87–1.11) | 0.79 |
| Ulcerative colitis | 1.27 (1.06–1.53) | 1.28 (1.06–1.54) | 0.86 (0.71–1.03) | 0.86 (0.71–1.03) | **0.0023** |

Italics: p < 0.05

Bold and italics: p < 0.0056

ADHD attention-deficit/hyperactivity disorder, CI confidence interval, OR odds ratio, SLE systemic lupus erythematosus

^a Age was categorized into four, years of age in 2015: 4–10; 11–15; 16–20; 21–48 and adjusted for as a nominal covariate
Psoriasis, Crohn’s disease and ulcerative colitis

As a robust positive association between psoriasis and ADHD was identified, this association was further examined, both in regards to psoriasis case definition and age- and period effects. The supplementary analyses confirmed the results of the primary analyses (see supplementary material for both specification of analyses and results).

The diagnoses CD and UC partly overlapped as 2334 individuals in the primary analyses were defined as having both conditions (37.1% of the CD patients and 21.3% of the UC patients). Supplementary analyses were conducted after redefining all individuals with both CD and UC as having neither. The results confirmed the positive associations in females, and the interaction by sex, but the negative associations in males were now not present (see supplementary material for both specification of analyses and results). To assess age- and period effects of ADHD on CD and UC, analyses stratified on birth years, 1967–1985 and 1986–2011, were conducted. For CD, the results were in line with the main analyses for both individuals born 1967–1985 and those born 1986–2011, including the sex-effects. However, for UC, the positive association in females, and negative association in males, were only noted in those born 1967–1985. For those born 1986–2011, no associations were noted (see supplementary material for further specification of analyses and results).

Discussion

In our large cross-sectional study based on population-wide registries, ADHD was clearly and positively associated with psoriasis. This association was present regardless of sex, but with a significantly stronger association in females than males. Furthermore, in females, ADHD was positively associated with CD and UC. In contrast, among males, ADHD showed a negative association with CD, and a similar tendency with UC.

Psoriasis is a skin disorder characterized by red scaly skin plaques, papules or patches and is generally considered an autoimmune disease [43]. The etiology behind psoriasis is complex, including environmental and lifestyle factors [50, 53, 59] and several genetic risk variants have been identified, mainly in and around genes involved in the immune response and skin barrier regulation [60]. In agreement with our findings, a Danish registry-based study noted a possible association between psoriasis and ADHD [21]. However, the association was not statistically significant (p = 0.09), which may be due to the study’s prospective study design where the autoimmune diseases had to debut prior to ADHD. In contrast, we utilized a cross-sectional design. Moreover, we investigated both children and adults, 4–48 years of age at linkage, whereas the Danish study only examined children and young adults, 5–22 years old at linkage, which lead to a smaller study sample. In addition, many of the individuals in the Danish study were simply too young to have developed psoriasis [59] or to have been diagnosed with ADHD [1].

Several different mechanisms may account for the association between ADHD and psoriasis. A recent family-based epidemiological study reported a significant genetic correlation between ADHD and psoriasis [61], indicating that there could be pleiotropic genetic effects in shared risk pathways. For example, complement factor C3 is highly expressed in both psoriatic lesions [62] and is important for synaptic pruning in the brain [63]. Lifestyle and environmental factors associated with ADHD, such as smoking and high BMI [20, 47, 48, 52], may also provoke psoriasis [50, 53]. However, in our mother analyses, adjustment for these risk factors did not attenuate the association, implying alternative etiological pathways [57, 58]. Furthermore, emotional and social stressors associated with ADHD [4, 64] could perhaps trigger psoriasis in predisposed individuals [65].

### Table 4

| Condition          | n     | OR (95% CI) | n      | OR (95% CI) |
|--------------------|-------|-------------|-------|-------------|
| ADHD               | 5636  |             | 1814  |             |
| Crohn’s disease    | 1225  | 1.77 (1.23–2.54) | 329   | 2.27 (1.29–4.01) |
| Psoriasis          | 14,226| 1.62 (1.44–1.81) | 3919  | 1.39 (1.12–1.72) |
| Ulcerative colitis | 2479  | 1.87 (1.42–2.46) | 676   | 2.00 (1.24–3.22) |

**ADHD** attention-deficit/hyperactivity disorder, **BMI** body mass index, **CI** confidence interval, **OR** odds ratio

---

**a** Restricted to females with information on smoking

**b** Restricted to females with information on BMI
CD and UC are both diseases primarily affecting the gastrointestinal system [51]. They are considered separate disease entities, but share many similarities, both clinically and etiologically, and are referred to collectively as inflammatory bowel disease (IBD). More than 150 genetic risk variants have been identified for both, many of which are shared, and environmental factors are highly implicated in the etiology [51, 66, 67]. In a study from Taiwan, ADHD was associated with UC, but not CD [22]. However, the authors did not report sex-specific effects, raising the possibility that the common estimate may be biased, and that the sex-specific effects present in our study, were not identified. Moreover, the prevalence-ratio of CD to UC was > 10:1 among the controls, indicating possible age-effects in addition to ethnic differences.

The increased odds of CD and UC in females with ADHD, with a reverse relation in males is striking. In addition, ADHD females had significantly higher odds of psoriasis than ADHD males. Sex, including both hormonal and non-hormonal influences, is a key determinant of immune system functioning [33, 34], brain development, neural functioning and psychiatric disease [30, 31, 38, 39, 68, 69]. A possible etiology for the sex-specific effects may involve glial cells, which are neuron-and homeostasis-supportive cells of the nervous system with immunomodulatory properties [33, 68, 70]. Glial cells have been shown to modulate sex-determined neurodevelopmental processes, including synaptic patterning and neurite pruning [68, 69]. Further, there are studies suggesting a role for glial cells located along the gut in the etiology of CD and UC, in addition to several other gastrointestinal disorders [70].

Genetically, pleiotropic associations between psychiatric disorders and autoimmune diseases have been reported [16], and so have sex-specific reverse genetic effects [36, 37]. Thus, we might hypothesize that the inverse associations observed in our study could be the result of pleiotropic variants, exhibiting sex-specific associations in opposite directions in either ADHD and/or IBD. Another potential mechanism could be that there is a tendency for more genetic variants positively associated with both ADHD and IBD to be located on the X-chromosome, while on the Y-chromosome, there is a greater burden of variants positively associated with ADHD, but negatively associated with IBD [35]. As the sex chromosomes have been largely ignored in GWASs owing to analytical difficulties, this is an area where further research is warranted.

Alternatively, smoking and BMI may play a role in the sex-discordant associations between ADHD and IBD [20, 47, 48, 52, 56]. However, adjustment for these potential mediators did not affect the associations much in our mother analyses, implying that they are weak mediators. Further, smoking has been shown to protect against UC, but confer risk for CD [51] and can consequently not easily explain our results as we then would have expected a negative association between ADHD and UC in females. Regarding BMI, prospective studies have only associated premorbid BMI with CD and not UC [56], which is not in agreement with our findings.

It could be that living with ADHD as a female gives rise to more stress, for example through social expectations and cultural norms, which again might lead to more autoimmunity [51, 65] and potentially, the sex-specific associations. However, one study showed that even though ADHD symptoms predispose to more stressful life events, female sex has been shown not to predispose to more stressful life events among those with ADHD symptoms [64].

Our study has several strengths. The use of compulsory population-wide registries minimize the risk of selection bias, and may provide the statistical power needed to investigate potential associations between ADHD and different autoimmune diseases. Further, the compulsory registration of prescription data protects against follow-up bias. However, we do not have information on medication given to hospital inpatients and nursing homes. Considering that the individuals in the primary analyses were all under 50 years, and that chronic diseases were investigated, we assume these factors to be of minor importance.

Another strength is the possibility to adjust for smoking and BMI in the mother analyses to assess mediating effects. However, we make the assumption that BMI and smoking at last registered pregnancy is “representative” of lifetime status up to 2015, which is sub-optimal. As the mother analyses were based on females, the generalizability to males could be questioned. Nonetheless, we consider it biologically unlikely that the positive association between psoriasis and ADHD is mediated purely by smoking and BMI in males, but not in females. In addition, several types of bias may occur as the mother analyses were based on only females who had given birth, and many autoimmune diseases are associated with reduced fertility [71], again possibly affecting the generalizability of the study. We are also aware that adjusting for intermediate variables, as we did in the mother analyses, may introduce collider stratification bias due to unmeasured variables affecting both smoking, BMI and the autoimmune diseases [57, 58]. Caution should therefore be exercised in the interpretation of these analyses. Also, we had problems with missing data for both smoking and BMI.

In Norway, the prescription of medication used in the treatment of ADHD is restricted and the drugs are only prescribed after thorough diagnostic evaluation in specialist health care. ADHD patients as defined by dispensed drugs is therefore presumably specific for ADHD. Nonetheless, we have missed patients who used ADHD medication only prior to 2004, and those who have never been prescribed medications due to contraindications, mild symptoms or patients who declined pharmacological treatment. However,
a previous study using similar data from the same period, demonstrated that only 17% of registered ADHD patients had not received ADHD medication [24]. Furthermore, our ADHD case definition includes individuals who in 2004–2008 were prescribed stimulants for treatment of narcolepsy, but as this is a very minor number, it should not influence the results.

Dispensed medication and reimbursement codes (ICD-10 codes and ICPC codes as indications for dispensed medication) were used as proxies for autoimmune diseases. Thus, our definitions of autoimmune diseases may not capture all patients. For example, patients with primary-progressive multiple sclerosis, which constitute 10–15% of multiple sclerosis patients, will often not be identified by our approach as until recently there have been limited pharmacological treatment options for this group [72]. Further, the reimbursement codes may not always be used correctly. Despite the limitations of our disease identification, we believe that a drug prescribed with a reimbursement code, indicates thorough diagnostics, especially considering that many of the drugs may have serious side effects and are not used without due consideration.

We found no robust statistically significant associations between ADHD and the autoimmune diseases iridocyclitis, rheumatoid arthritis, SLE, ankylosing spondylitis, multiple sclerosis or type 1 diabetes. This could be due to a genuine lack of association between these autoimmune diseases and ADHD. Nonetheless, it could be that the low share of individuals born prior to 1990 who have dispensed ADHD-medication (supplementary Fig. 1) as compared to those born later, may reflect ADHD symptom remission before 2004 when the NorPD was established, or historical underdiagnosis and undertreatment of ADHD. Consequently, these ADHD individuals are not identified by our case definition. On the contrary, many autoimmune diseases are diagnosed later in life. Combined, our study may be inadequate for discovering associations between ADHD and autoimmune diseases with late debut. This may also partly explain the absence of any associations between ADHD and UC among individuals born 1985–2011 (supplementary material).

As our study is cross-sectional and we exclude all deceased or emigrated individuals, this may constitute a source of bias as ADHD is associated with increased mortality [73] and so are many of the autoimmune diseases [74, 75]. However, we do not believe that such bias underlies the findings of our study. First, the increased mortality associated with ADHD, mostly accidents, is unlikely to differ by autoimmune diseases nor constitute a large absolute number. Second, our cohort is relatively young with the oldest in the main analyses being 48 years of age at linkage. Therefore, most of the cohort is too young for cardiovascular death, which constitute a large portion of the mortality associated with autoimmune diseases [74–76]. In addition, the findings regarding CD and psoriasis could be identified among younger individuals in the birth year-stratified analyses. On the other hand, not excluding individuals who died or emigrated before the end of study could have lead to bias. Individuals who received ADHD medication after 2004, and thus captured by our study as ADHD patients, but developed autoimmune diseases and died or emigrated before 2008 would be lost.

Another source of bias could be that ADHD patients, already in contact with the health services, may get a diagnosis of comorbid diseases more easily than individuals who do not have an established link with the health services. However, one should then expect increased odds of all autoimmune diseases, and for both females and males, which was not the case. The symptoms of an autoimmune disease could also be mistaken for ADHD symptoms. For example the itch of psoriasis could lead to lower sleep quality and daytime sleepiness [77, 78], which may be mistaken for the impaired attention of ADHD. Yet, one would again expect increased odds of all autoimmune diseases.

In conclusion, our study supports previous reports on associations between ADHD and autoimmune diseases, and adds new knowledge about sex-specific associations and even reverse direction by sex for some associations. Our results also suggest that these associations are not mediated by smoking or BMI. Overall, our study suggests that sex-specific immune-mediated neurodevelopment may play a role in ADHD etiology, warranting further investigation. Future studies investigating the relationship between autoimmunity and neuropsychiatric disorders should be aware of sex-specific effects.

Acknowledgements The authors would like to thank Ingeborg M. Bachmann, Bjørg-Tilde Fenvang, Eystein S. Husebye, Rolv Skjærven, Berit Skretting Solberg and Tetyana Zayats for valuable discussions. This study was supported by the Western Norway Regional Health Authorities (Helse Vest), Stiftelsen Kristian Gerhard Jebsen, the University of Bergen, The Norwegian national research network for ADHD, and the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 667302 (CoCA).

Compliance with ethical standards

Ethical approval The study was approved by the Regional Committee for Medical and Health Research Ethics of Western Norway (2012/2223/REK vest) and the Norwegian Data Inspectorate. The study has been conducted in accordance with 1964 Declaration of Helsinki and its later amendments.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate

 Springer
credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Farraoe SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, Rohde LA, Sonuga-Barke EJ, Tannock R, Franke B (2015) Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 1:15020. doi:http://doi.org/10.1038/nrdp.2015.20

2. Jensen CM, Steinhausen HC (2015) Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Deficit Hyperact Disord 7(1):27–38. doi:http://doi.org/10.1007/s12402-014-0142-1

3. Sobanski E (2006) Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 256(Suppl 1):i26–i31. doi:http://doi.org/10.1007/s00406-006-1004-4

4. Halmøy A, Fasmer OB, Gillberg C, Haavik J (2009) Occupational transition, developmental continuities and life circumstances in the English and Romanian Adoptees study. J Child Psychol Psychiatry 50(10):1113–1125. doi:http://doi.org/10.1111/jcpp.12576

5. Kennedy M, Kreppner J, Knights N, Kumsta R, Maughan B, Golm D, Rutter M, Schlotz W, Sonuga-Barke EJ (2016) Early severe institutional deprivation is associated with a persistent variant of adult attention-deficit/hyperactivity disorder: clinical presentation, developmental continuities and life circumstances in the English and Romanian Adoptees study. J Child Psychol Psychiatry 57(10):1113–1125. doi:http://doi.org/10.1111/jcpp.12576

6. Halmyo A, Klungsoyr K, Haavik J (2009) Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment. A cross-sectional study of 510 clinically diagnosed adult ADHD patients. J Atten Disord 13(2):157–187

7. Chang Z, Lichtenstein P, Asherson PJ, Larsson H (2013) Developmental twin study of attention problems: high heritabilities throughout development. JAMA Psychiatry 70(3):311–318. doi:http://doi.org/10.1001/jamapsychiatry.2013.287

8. Larsson H, Chang Z, D’Onofrio BM, Lichtenstein P (2014) The heritability of clinically diagnosed attention deficit hyperactivity disorder across the lifespan. Psychol Med 44(10):2223–2229. doi:http://doi.org/10.1017/s0033291713002493

9. Kennedy M, Krepner J, Knights N, Kumsta R, Maughan B, Golm D, Rutter M, Schlotz W, Sonuga-Barke EJ (2016) Early severe institutional deprivation is associated with a persistent variant of adult attention-deficit/hyperactivity disorder: clinical presentation, developmental continuities and life circumstances in the English and Romanian Adoptees study. J Child Psychol Psychiatry 57(10):1113–1125. doi:http://doi.org/10.1111/jcpp.12576

10. Halmyo A, Klungsoyr K, Skjaerven R, Haavik J (2012) Pre- and perinatal risk factors in adults with attention-deficit/hyperactivity disorder. Biol Psychiat 71(5):434–441. doi:http://doi.org/10.1016/j.biopsych.2011.11.036

11. Meltzer A, Yan LC, Cohen J, Weissman MM, Padian SK, Kessler RC, Corvin A, Craddock N, Daly MJ, Datta S, Donohoe P, Duan J, Dudbridge F, Fanous A, Freedman R, Freimer NB, Fried M, Gill M, Gurling H, De Haan L, Hamshere ML, Hartmann AM, Holmans PA, Kahn RS, Keller MC, Kenny E, Kirov GK, Krabbendam L, Krasucki R, Lawrence J, Lencz T, Levinson DF, Lieberman JA, Lin DY, Linszen DH, Magnusson PK, Maier W, Malhotra AK, Mattheisen M, Mattingsdal M, McCarroll SA, Medeiros H, Melle I, Milanova V, Myin-Germeys I, Neale BM, Ophoff RA, Owen MJ, Pimm J, Purcell SM, Puri V, Quested DJ, Rossin L, Ruderfer D, Sanders AR, Shi J, Sklar P, St Clair D, Stroup TS, Van Os J, Visscher PM, Wiersma D, Zammit S, Bridges SL Jr, Choi HK, Coen MJ, de Vries N, Diep D, Greenberg JD, Huizinga TW, Padyukov L, Siminovich KA, Tak PP, Worthington J, De Jager PL, Denny JC, Gregersen PK, Klareskog L, Mariette X, Plenge RM, van Laar M, van Riel P (2015) New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. Int J Epidemiol 44(5):1706–1721. doi:http://doi.org/10.1093/ije/dyv136

12. Woehl EH, Franklin T, Iwata M, Duman RS (2016) Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci 17(8):497–511. doi:http://doi.org/10.1038/nrn.2016.69

13. Careaga M, Rogers S, Hansen RL, Amaral DG, Van de Water J, Ashwood P (2017) Immune endophenotypes in children with Autism spectrum disorder. Biol Psychiat 81(5):434–441. doi:http://doi.org/10.1016/j.biopsych.2015.08.036

14. Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21(12):1696–1709. doi:http://doi.org/10.1038/mp.2016.3

15. Rout UK, Mungan NK, Bhosche DM (2012) Presence of GAD65 autoantibodies in the serum of children with autism or ADHD. Eur Child Adolesc Psychiatry 21(3):141–147. doi:http://doi.org/10.1007/s00787-012-0245-1

16. Wang Q, Yang C, Gelertner J, Zhao H (2015) Pervasive pleiotropy between psychiatric disorders and immune disorders revealed by integrative analysis of multiple GWAS. Hum Genet 134(11–12):1195–1209. doi:http://doi.org/10.1007/s00439-015-1596-8

17. Sellgren C, Frisell T, Lichtenstein P, Lindell M, Askling J (2014) The association between schizophrenia and rheumatoid arthritis: a nationwide population-based Swedish study on intraindividual and familial risks. Schizophr Bull 40(6):1552–1559. doi:http://doi.org/10.1093/schbul/bsh054

18. Bouget JG, Goncalves VF, Spain SL, Finucane HK, Raychaudhuri S, Kennedy JL, Knight J (2016) Genome-wide association studies suggest limited immune gene enrichment in schizophrenia compared to 5 autoimmune diseases. Schizophr Bull 42(5):1176–1184. doi:http://doi.org/10.1093/schbul/sbw059

19. Hegvik T, Husebye ES, Haavik J (2014) Autoantibodies targeting neurotransmitter biosynthetic enzymes in attention-deficit/hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 23(2):115–117. doi:http://doi.org/10.1007/s00787-013-0429-3

20. Instanes JT, Klungsoyr K, Halmyo A, Fasmer OB, Haavik J (2016) Adult ADHD and comorbid somatic disease: a systematic literature review. J Atten Disord. doi:http://doi.org/10.1177/1087054715609138

21. Nielsen PB, Benders ME, Dalsgaard J, (2017) Associations between autoimmune diseases and attention-deficit/hyperactivity disorder: a Nationwide study. J Am Acad Child Adolesc Psychiatry 56(3):234–240.e231. doi:http://doi.org/10.1016/j.jaac.2016.12.010

22. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, Chen TJ, Bai YM (2017) Comorbidity of allergic and autoimmune diseases among patients with ADHD. J Atten Disord 21(3):219–227. doi:http://doi.org/10.1177/1087054714546868

23. Butwicke A, Lichtenstein P, Frisen L, Aimqvist C, Larsson H, Ludvigsson JF (2017) Celiac disease is associated with childhood
psychiatric disorders: a Population-Based Study. J Pediatr.
doi:http://dx.doi.org/10.1016/j.jpeds.2017.01.043

24. Instantes JT, Halmøy A, Engeland A, Haavik J, Furu K, Klung-
soyr K (2017) Attention-deficit/hyperactivity disorder in off-
spring of mothers with inflammatory and immune system dis-
eases. Biol Psychiат81(5):452–459. doi:http://dx.doi.org/10.1016/j.
biopsych.2015.11.024

25. The Network and Pathway Analysis Subgroup of the Psychiatric
Genomics Consortium (2015) Psychiatric genome-wide associ-
tion study analyses implicate neuronal, immune and histone path-
ways. Nat Neurosci 18(2):199–209. doi:http://dx.doi.org/10.1038.
nm.3922

26. Okun E, Griffissen K, Baron B, Roberts NJ, Castro K, Pita
M, Cheng A, Maghil MR, Wan R, Ashery U, Mattson MP (2010)
Toll-like receptor 3 inhibits memory retention and constricts adult hippocampal neurogenesis. Proc Natl Acad Sci USA 107(35):15625–15630. doi:http://dx.doi.org/10.1073.
pnas.1005807107

27. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD,
Agerbo E, Børglum AD, Beaudet AL, Benjamini Y, Bower L, Braun
RE, Brown SDM, Chesler EJ, Dickinson ME, Flenniken AM,
Fuchs H, Angelis MH, Gao X, Guo S, Greenaway S, Heller R,
HeraULT Y, Justice MJ, KurputaNoV, Lelliott CJ, Lloyd KCK, Mal-
lon AM, Mank JE, Masuya H, Mckelrie C, Meihean TF, Mott RF,
Murray SA, Parkinson H, RamireZ-SolIs R, Santos L, Seavitt JR,
Smedly D, Sorg T, Speak AO, Steel KP, Svenson KL, Wakanaka
S, West D, Wells S, Westerberg H, Yanacoba S, White JK (2017)
Prevalence of sexual dimorphism in mammalian phenotypic traits.
Nat Commun 8:15475. doi:http://dx.doi.org/10.1038/ncomms15475

28. Winkler TW, Justice AE, Graff M, Barata L, Feitosa MF, Chl
S, Czajkowski J, Esko T, Fall T, Kilpelainen TO, Lu Y, Magi R,
Mihaltov E, Pers TH, Rueger S, Teumer A, Ehret GB, Ferreira T,
Teared-Costa NL, Karjalainen J, Lagou V, Mahajan A, Nein-
ast MD, Prokopenko I, Simino J, Teslovich TM, Jansen R,
Wessna J, White CC, Absher D, Alhuwaila TS, Ahmed S,
Albrecht E, Alves AC, Bragg-Gresham JL, de Craen AJ, Biss JC,
Bonnefond A, Bouchier G, Cadby G, Cheng YC, Chiang CW,
Delgado G, Demirkan A, Ducker N, Eklund N, Eriksdottir G,
Eriksjon K, Feenstra B, Fischer K, Frau F, Galesloot TE, Geller
F, Goel A, Gorski M, Grammer TB, Gustafsson S, Haitjema S,
Hottenga JI, Huffman JE, Jackson AU, Jacobs KB, Johansson
A, Kaakinen M, Kleber ME, Lahti J, Mateo Leach I, Lehe B,
Liu Y, Lo KS, Lorentzon M, Luan J, Madden PA, Mangino M,
McKnight B, Medina-Gomez C, Monda KL, Montasser ME,
Muller G, Muller-Nurasyid M, Nolte I, Panoutsopoulou K,
Pascoe L, Paternoster L, Rayner NW, Renstrom F, Rizzi F, Rose
LM, Ryan KA, Salo P, Sanna S, Scharnagl H, Shi J, Smith AV,
Southam L, Stanacakova A, Steinhorsdottir V, Strawbridge RJ,
Sung YJ, Tachmazidou I, Tanaka T, Thorleifsson G, Trompet S,
Twyer JP, Vanendunp L, Van der Laan SW, Van der Velde N, Van,
setten N, Von Vliet-Ostapchouk JV, Verweij N, Vlachopoulos E,
Waite LL, Wang SR, Wang Z, Wild SH, Willenberg C, Wilson JF,
Wong A, Yang J, Yong L, Yerges-Armstrong LM, Yu L, Zhang W,
Zhao JD, Andersson EA, Baker SJ, Baldassarre D, Banasik K,
Barcella M, Barlassina C, Bellis C, Benaglio P, Blanjer G, Bluhmer M,
Bonnet F, Bonnycastle LL, Boyd HA, Bruinenberg M, Buchman AS,
Campbell H, Chen YD, Chines PS, Claudi-Boehm S, Cole J, Collins FS,
de Geus EJ, De Grooth DC, Dimiroti M, Duan J, Enroth S, Eury E,
Farmer AE, Forouhi NG, Friedman N, Gejman PV, Gigante B,
Glorioso N, Go AS, Gottsman O, Grassler J, Grallert H, Grarup
N, Gu YM, Broer L, Ham AC, Hansen T, Harris TB, Hartman CA,
Hassinen M, Hastie N, Hattersley AT, Heath AC, Henders AK, Hettander D, Hillege H, Holmen O, Hovingh KG,
Hui J, Husemoen LL, Hutri-Kahonen N, Hysing P, Illig T, De
Jager PL, Jalilzadeh S, Jorgensen T, Jukema JW, Jurnala M,
Kanoni S, Karaleftheri M, Khaw KT, Kinnunen L, Kittner SJ,
Koenig W, Kolcic I, Kovacs P, Krarup NT, Kratzer W, Kruger
A, Kaakinen M, Kyriakou T, Langenberg C, Lannfelt L,
Larsson H, Husemoen LL, Hutri-Kahonen N, Hysing P, Illig T, De
Jager PL, Jaliilzadeh S, Jorgensen T, Jukema JW, Jonila M,
Kanoni S, Karaleftheri M, Khaw KT, Kinnunen L, Kittner SJ,
Koenig W, Kolcic I, Kovacs P, Krarup NT, Kratzer W, Kruger
A, Kaakinen M, Kyriakou T, Langenberg C, Lannfelt L,
Larsson H, Husemoen LL, Hutri-Kahonen N, Hysing P, Ilig T, De
Jager PL, Jaliilzadeh S, Jorgensen T, Jukema JW, Jonila M,
Kanoni S, Karaleftheri M, Khaw KT, Kinnunen L, Kittner SJ,
Koenig W, Kolcic I, Kovacs P, Krarup NT, Kratzer W, Kruger
A, Kaakinen M, Kyriakou T, Langenberg C, Lannfelt L,
Larsson H, Husemoen LL, Hutri-Kahonen N, Hysing P, Ilig T, De
Jager PL, Jaliilzadeh S, Jorgensen T, Jukema JW, Jonila M,
Kanoni S, Karaleftheri M, Khaw KT, Kinnunen L, Kittner SJ,
Koenig W, Kolcic I, Kovacs P, Krarup NT, Kratzer W, Kruger
A, Kaakinen M, Kyriakou T, Langenberg C, Lannfelt L,
Larsson H, Husemoen LL, Hutri-Kahonen N, Hysing P, Ilig T, De
Jager PL, Jaliilzadeh S, Jorgensen T, Jukema JW, Jonila M,
Kanoni S, Karaleftheri M, Khaw KT, Kinnunen L, Kittner SJ,
Koenig W, Kolcic I, Kovacs P, Krarup NT, Kratzer W, Kruger
A, Kaakinen M, Kyriakou T, Langenberg C, Lannfelt L,
Larsson H, Husemoen LL, Hutri-Kahonen N, Hysing P, Ilig T, De
Jager PL, Jaliilzadeh S, Jorgensen T, Jukema JW, Jonila M,
smokers with childhood attention-deficit/hyperactivity disorder (AD/HD) history: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 264(5):379–389. doi:http://doi.org/10.1007/s00406-014-0497-5

49. Costenbader KH, Feskanich D, Mandl LA, Karlson EW (2006) Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 119(6):503.e501–503.e509. doi:http://doi.org/10.1016/j.amjmed.2005.09.053

50. Li W, Han J, Choi HK, Qureshi AA (2012) Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 175(5):402–413. doi:http://doi.org/10.1093/aje/kwr325

51. Ananthakrishnan AN (2015) Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12(4):205–217. doi:http://doi.org/10.1038/nrgastro.2015.34

52. Cortese S, Moreira-Maia CR, St Fleur D, Morcillo-Penalver C, Rohde LA, Fararone SV (2016) Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 173(1):34–43. doi:http://doi.org/10.1176/appi.ajp.2015.15020266

53. Setty AR, Curhan G, Choi HK (2007) Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med 167(15):1670–1675. doi:http://doi.org/10.1001/archinte.167.15.1670

54. Mokry LE, Ross S, Timpson NJ, Sawcer S, Davey Smith G, Richards JB (2016) Obesity and multiple sclerosis: a Mendelian Randomization Study. PLoS Med 13(6):e1002053. doi:http://doi.org/10.1371/journal.pmed.1002053

55. Lu B, Hiraki LT, Sparks JA, Malpeis S, Chen CY, Awosogba JA, Arkema EV, Costenbader KH, Karlson EW (2014) Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 73(11):1914–1922. doi:http://doi.org/10.1136/annrheumdis-2014-205459

56. Singh S, Dalai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ (2017) Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol 14(2):110–121. doi:http://doi.org/10.1038/nrgastro.2016.181

57. Richiardi L, Bellocco R, Zignan D (2013) Mediation analysis in epidemiology: methods, interpretation and bias. Int J Epidemiol 42(5):1511–1519. doi:http://doi.org/10.1093/ije/dyt127

58. Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology (Cambridge, Mass) 20(4):488–495. doi:http://doi.org/10.1097/EDE.0b013e3181b6c3d6

59. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2):377–385. doi:http://doi.org/10.1038/jid.2012.339

60. Tsio LC, Spain SL, Knight J, Ellinghaus E, Sturt PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, Kang HM, Allen MH, McManus R, Novelli G, Samuelsson L, Schalkwijk J, Stahle M, Burden AD, Smith CH, Cork MJ, Estivill X, Bowcock AM, Krueger GG, Wegner W, Worthington J, Tazi-Ahnini R, Nestle FO, Hayday A, Hoffmann P, Winklemann J, Wijmenga C, Langford C, Edkins S, Andrews R, Blackburn H, Strange A, Band G, Pearson RD, Vukcevic D, Spencer CC, Deloukas P, Mrowietz U, Schreiber S, Weidinger S, Koks S, Kingo K, Esko T, Metspalu A, Lim HW, Voorhees JJ, Weichenthal M, Wichmann HE, Chandran V, Rosen CF, Rahman P, Gladman DD, Griffiths CE, Reis A, Kere J, Nair RP, Franke A, Barker JN, Abecasis GR, Elder JT, Trembath RC (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44(12):1341–1348. doi:http://doi.org/10.1038/ng.2467

61. Wang K, Gaitsch H, Poon H, Cox NJ, Rzhetsky A (2017) Classification of common human diseases derived from shared genetic and environmental determinants. Nat Genet. doi:http://doi.org/10.1038/ng.3931
62. Schonthaler HB, Guinea-Viniegra J, Wculek SK, Ruppen I, Ximenez-Ebeld P, Guio-Carrion A, Navarro R, Hogg N, Ashman K, Wagner EF (2013) S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity 39(6):1171–1181. doi:http://doi.org/10.1016/j.immuni.2013.11.011

63. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopher-Johnson P, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik AR, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131(6):1164–1178. doi:http://doi.org/10.1016/j.cell.2007.10.036

64. Friedrichs B, Igl W, Larsson H, Larsson JO (2012) Coexistence of psychiatric problems and stressful life events in adults with symptoms of ADHD—a large Swedish population-based study of twins. J Atten Disord 16(1):13–22. doi:http://doi.org/10.1177/1087054710376909

65. Hunter HJ, Griffiths CE, Kley CE (2013) Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol 169(5):975–984. doi:http://doi.org/10.1111/bjd.12478

66. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleyten I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andrews V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bunter A, Boucher G, Brand S, Buning C, Cohain A, Cichon S, D’Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellingham D, Ferguson LR, Franchimont D, Fransen K, Goyette P, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Gearry RB, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Rammohan KW, Selmak J, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. New Engl J Med 376(3):209–220. doi:http://doi.org/10.1056/NEJMoa1606468

67. Ximenez-Embun P, Guio-Carrion A, Navarro R, Hogg N, Ashman K, Wagner EF (2013) Ocrelizumab versus placebo in primary progressive multiple sclerosis. New Engl J Med 376(3):209–220. doi:http://doi.org/10.1056/NEJMoa1606468

68. Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015) Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 385(9983):2190–2196. doi:http://doi.org/10.1016/s0140-6736(14)61684-6

69. Gagnon V, Stene LC, Jønsson MG, Mikkelsen K, Kaufmann C, Magnussen P, Joner G, Njolstad PR, Skrivarhaug T (2017) Causes of death in people with psoriasis by sex: a nationwide population-based cohort study. Lancet 385(9983):2190–2196. doi:http://doi.org/10.1016/s0140-6736(14)61684-6

70. Dregan A, Chowienczyk P, Molokhia M (2017) Cardiovascular and type 2 diabetes morbidity and all-cause mortality among people with different chronic inflammatory disorders. Heart (British Cardiac Society). doi:http://doi.org/10.1136/heartjnl-2017-311214

71. Institute for Health Metrics and Evaluation (IHME) (2016) Global burden of disease—causes of death (COD) data visualization. http://vizhub.healthdata.org/cod. Accessed 25 July 2017

72. Institute for Health Metrics and Evaluation (IHME) (2016) Global burden of disease—causes of death (COD) data visualization. http://vizhub.healthdata.org/cod. Accessed 25 July 2017

73. Henry AL, Kyle SD, Bhandari S, Chisholm A, Griffiths CE, Bundy C (2016) Measurement, classification and evaluation of sleep disturbance in people with psoriasis: a systematic review. PLoS One 11(6):e0157843. doi:http://doi.org/10.1371/journal.pone.0157843

74. Henry AL, Kyle SD, Chisholm A, Griffiths CE, Bundy C (2017) A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis. Br J Dermatol. doi:http://doi.org/10.1111/bjd.15469